- Home
- NBTX vs AMRN Comparison
NBTX vs AMRN Comparison
Compare NBTX & AMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBTX
- AMRN
- Stock Information
- Founded
- NBTX 2003
- AMRN 1989
- Country
- NBTX France
- AMRN Ireland
- Employees
- NBTX N/A
- AMRN N/A
- Industry
- NBTX Biotechnology: Pharmaceutical Preparations
- AMRN Biotechnology: Pharmaceutical Preparations
- Sector
- NBTX Health Care
- AMRN Health Care
- Exchange
- NBTX Nasdaq
- AMRN Nasdaq
- Market Cap
- NBTX 201.9M
- AMRN 189.2M
- IPO Year
- NBTX 2020
- AMRN 1993
- Fundamental
- Price
- NBTX $3.75
- AMRN $0.59
- Analyst Decision
- NBTX Strong Buy
- AMRN Buy
- Analyst Count
- NBTX 1
- AMRN 1
- Target Price
- NBTX $12.00
- AMRN N/A
- AVG Volume (30 Days)
- NBTX 8.9K
- AMRN 991.3K
- Earning Date
- NBTX 09-18-2024
- AMRN 03-12-2025
- Dividend Yield
- NBTX N/A
- AMRN N/A
- EPS Growth
- NBTX N/A
- AMRN N/A
- EPS
- NBTX N/A
- AMRN N/A
- Revenue
- NBTX $45,220,186.00
- AMRN $241,021,000.00
- Revenue This Year
- NBTX N/A
- AMRN N/A
- Revenue Next Year
- NBTX N/A
- AMRN N/A
- P/E Ratio
- NBTX N/A
- AMRN N/A
- Revenue Growth
- NBTX 526.17
- AMRN N/A
- 52 Week Low
- NBTX $2.76
- AMRN $0.43
- 52 Week High
- NBTX $7.51
- AMRN $1.36
- Technical
- Relative Strength Index (RSI)
- NBTX 53.25
- AMRN 55.53
- Support Level
- NBTX $3.60
- AMRN $0.56
- Resistance Level
- NBTX $3.95
- AMRN $0.59
- Average True Range (ATR)
- NBTX 0.19
- AMRN 0.04
- MACD
- NBTX -0.01
- AMRN 0.00
- Stochastic Oscillator
- NBTX 38.18
- AMRN 71.91
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
About AMRN Amarin Corporation plc
Amarin Corp PLC is a biopharmaceutical company. It is focused on the commercialization and development of therapeutics to improve cardiovascular, or CV, health and reduce CV risk. Its commercialized product includes Vascepa.